Oxford Instruments Full-Year Results: Strong H2 Recovery and Record Order Book

So this was not a year of clean growth. The company was hit by a disrupted first half, including tariff issues, uncertainty around US academic funding, and slower-than-expected conversion of large Advanced Technologies orders into revenue.

That last point is important. Oxford Instruments did not miss out on the demand – it just did not book all of it as revenue yet. Larger, more complex systems for high-volume semiconductor customers take longer to install and recognise as sales. That is frustrating in the short term, but it is a better problem than weak demand.

Imaging & Analysis recovery – Belfast restructuring is finally paying off

Imaging & Analysis is still the group’s profit engine, and there are some encouraging signs here. Revenue fell 3.0% OCC to £314.7 million, but adjusted operating profit actually rose 2.3% OCC to £70.9 million, with margin improving by 120 basis points on that same basis to 23.3%.

That is a good effort. It suggests the Belfast restructuring, product mix changes and operational improvements are doing what they were supposed to do.

The company said the Belfast cameras and microscopy business cut its workforce by 20%, shifted towards higher contribution product lines and improved productivity. It also delivered an extra £5.6 million in cash flow from lower inventory. Not glamorous, but exactly the sort of operational tightening investors like to see after a weak patch.

Orders in Imaging & Analysis improved through the year and were up 8.4% in H2, leaving the full year up 1.3% OCC. That is not explosive, but after a rough first quarter it looks like a credible recovery.

Advanced Technologies and compound semiconductors – big opportunity, thin margins for now

This is where the excitement is. Advanced Technologies revenue fell 3.2% OCC to £108.5 million, and adjusted operating profit more than halved to £2.8 million. That pushed margin down to 2.6% from 5.6%.

On the face of it, that looks poor. But the explanation matters. The division is scaling up into larger, more automated semiconductor systems, which are more complex to build and slower to convert into revenue. On top of that, Severn Beach brought higher depreciation and maintenance costs, while the business continues to invest for growth.

The positive spin – and I think it is fair, not forced – is that this is a transition year. Orders tied to datacoms applications grew more than 200% in FY26, and micro LED also produced a £10 million order from a single customer. Management now expects high teens revenue growth in FY27 for the division, with margins moving significantly forward.

That does mean execution risk goes up. A record order book is great, but only if the company can deliver it efficiently and on time. Investors should watch that closely over the next 12 months.

NanoScience sale, cash returns and dividend growth – why the balance sheet matters

The disposal of NanoScience looks sensible. It brought in net cash proceeds of £42.4 million, sharpened the group’s focus, and improved margin mix. The sale also helped support £62.2 million of share buybacks during the year.

Net cash ended the year at £94.0 million, up from £84.4 million, despite £75.2 million being returned to shareholders through dividends and buybacks. That is a strong financial position, and it gives Oxford Instruments room to keep investing in research and development, capital expenditure and potentially acquisitions.

Cash conversion was 89% on a normalised basis. That is below last year’s 102%, but still solid. The dividend was lifted 6.3% to 23.6p, which adds to the message that management is confident about future growth rather than just patching up a bad year.

Oxford Instruments outlook for FY27 – my view on what matters next

There is plenty to like here. The second half improved, Imaging & Analysis margins were strong, Advanced Technologies orders were excellent, and the balance sheet is robust. For me, that combination makes this update more positive than the falling revenue and profit lines first suggest.

Still, it is not risk-free. Currency is expected to be a £3.2 million headwind to adjusted operating profit in FY27, academic demand remains softer, and Advanced Technologies has to prove it can turn its bumper order intake into profitable revenue at pace.

My take is that Oxford Instruments looks like a business that has done the hard part of resetting itself and is now trying to cash in on a real semiconductor growth opportunity. If execution holds up, FY26 may end up looking like the awkward in-between year before stronger growth returns. If execution slips, investors will quickly lose patience with the “jam tomorrow” argument.

Right now, the order book gives management the benefit of the doubt.